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Abstract 
The accumulation of the scrapie agent in lymphoid tissues following inoculation via 
the skin is critical for efficient neuroinvasion, but how the agent is initially 
transported from the skin to the draining lymph node is not known. Langerhans cells 
(LCs) are specialized antigen-presenting cells that continually sample their 
microenvironment within the epidermis and transport captured antigens to draining 
lymph nodes. We considered LCs probable candidates to acquire and transport the 
scrapie agent after inoculation via the skin. XS106 cells are dendritic cells (DCs) 
isolated from mouse epidermis with characteristics of mature LC cells. To investigate 
the potential interaction of LCs with the scrapie agent XS106 cells were exposed to 
the scrapie agent in vitro. We show that XS106 cells rapidly acquire the scrapie agent 
following in vitro exposure. In addition, XS106 cells partially degrade the scrapie 
agent following extended cultivation. These data suggest that LCs might acquire and 
degrade the scrapie agent after inoculation via the skin, but data from additional 
experiments demonstrate that this ability could be lost in the presence of 
lipopolysaccharide or other immunostimulatory molecules. Our studies also imply 
that LCs would not undergo maturation following uptake of the scrapie agent in the 
skin, as the expression of surface antigens associated with LC maturation were 
unaltered following exposure. In conclusion, although LCs or DCs have the potential 
to acquire the scrapie agent within the epidermis our data suggest it is unlikely that 
they become activated and stimulated to transport the agent to the draining lymph 
node. 
 
 
Introduction 
The transmissible spongiform encephalophathies (TSEs or prion diseases) are 
infectious, fatal, neurodegenerative diseases. During disease, PrPSc, an abnormal, 
relatively proteinase-resistant isoform of the host glycoprotein PrPC accumulates 
with infectivity in affected tissues.1 PrPSc is considered to constitute a major, or 
possibly sole component of the infectious TSE agent.2 The deposition of PrPSc within 
the brains of most TSE-affected hosts is usually accompanied with 
neurodegeneration. 
Many natural infections with TSE agents, such as natural sheep scrapie, bovine 
spongiform encephalopathy, chronic wasting disease in mule deer and elk and 
variant Creutzfeldt–Jakob disease (vCJD) in humans, are likely to be acquired orally. 
However, studies in mice show that skin scarification is also an effective means of 
scrapie transmission.3 This suggests that some natural TSE cases might be 
transmitted through skin lesions in the mouth4 or through sites of skin trauma 
during close contact with infected animals. The potential to transmit vCJD in 
humans iatrogenically during surgical or dental procedures is a current concern. 
Following inoculation of mice with the scrapie agent via the skin,5,6 peritoneal 
cavity7,8 or orally9 neuroinvasion usually occurs after the agent accumulates in 
association with follicular dendritic cells (FDCs) in the germinal centres of lymphoid 
tissues. 
How TSE agents are transported initially from the site of exposure, such as the 
gastrointestinal tract or the skin, to the germinal centres where they replicate is not 
known. FDCs could directly trap PrPSc or other agent-associated molecules in a 
complement-bound complex.10,11 TSE agents might also be delivered to germinal 
centres following their uptake and transportation by mobile cells. Migratory bone 
marrow-derived DCs are a distinct lineage from tissue-fixed, stromal-derived 
FDCs.12These DCs circulate continually throughout the host's tissues and tissue 
fluids sampling antigens and transporting them to lymphoid tissues.13 Langerhans 
cells (LCs) are a subset of migratory DCs that are situated within the epidermis and 
migrate to the draining lymph node following antigen encounter.13 DCs and LCs are 
considered to provide potential mechanisms for the transmission of some viruses 
into the skin.14,15 A subpopulation of migratory DCs might also play a role in the 
transportation of PrPSc from the intestine to the mesenteric lymph node.16 These 
observations suggested to us that LCs were plausible candidates for the 
transportation of the scrapie agent from the skin to draining lymph nodes. XS106 
cells are a well-established DC cell line isolated from mouse epidermis with 
characteristics of mature LCs. These cells strongly resemble LCs in vivo and potently 
activate naive T lymphocytes in allogeneic mixed lymphocyte reactions.17 Our 
preliminary investigations suggested that XS106 cells had the potential to acquire 
and degrade PrPSc.18 In the current study these cells were used to further explore the 
potential interactions of LCs with the scrapie agent following in vitro exposure. 
 
Materials and metodhs 
Culture of cell lines 
The XS52 and XS106 cell lines (kind gifts from Professor Akira Takashima, 
University of Texas South-western, TX) are long-established dendritic cell lines 
derived from the epidermis of newborn mice.17,19 These cell lines were cultured in 
complete RPMI-1640 medium (cRPMI) which contained 2 mM L-glutamine, 1 
mM sodium pyruvate, 10 mM HEPES buffer, 0·25 µg/ml antibiotic–antimycotic 
solution (A5955, containing penicillin, streptomycin and amphotericin B), 50 µM 2-
β-mercaptoethanol, 1% non-essential amino acids (all from Sigma, Poole) and 10% 
heat-inactivated fetal calf serum (Invitrogen, Paisley). The medium used to cultivate 
the XS52 cells was supplemented further with 2 ng/ml murine recombinant 
granulocyte-macrophage colony stimulating factor (GM-CSF; R&D Systems, 
Abingdon, Oxon) and 10% (v/v) culture supernatant derived from the NS47 
fibroblast cell line. The medium used to cultivate the XS106 cells was supplemented 
with 0·5 ng/ml murine recombinant GM-CSF and 5% (v/v) culture supernatant 
derived from the NS47 fibroblast cell line. All cell lines were cultured at 37° in a 5% 
CO2/air atmosphere. 
Upon receipt, cells were passaged four times to obtain a large batch culture and then 
cryopreserved. For each individual experiment a new vial of cells was revived and 
expanded for 10 days in culture prior to use to ensure homogeneity between cell 
populations. 
 
Flow cytometry 
Cells were harvested and viable cell numbers determined by trypan blue dye 
exclusion. Cells were pelleted (300 g for 10 min at 4°) and resuspended in FACS 
buffer [phosphate buffered saline (PBS) pH 7·4 containing 0·1% bovine serum 
albumin (BSA), 0·1% sodium azide and 0·02% ethylene diamine tetra-acetic acid 
(EDTA)] to give 1 × 106 cells per 100 µl buffer. Non-specific binding of 
immunoglobulins to FcRIII and FcRII receptors was blocked with 0·1 µg of mouse 
monoclonal antibody (mAb) CT-17·2 specific for CD16/32 (FcRIII/FcRII receptor; 
Caltag, Burlingame, CA). Cells were then incubated with one of the following 
fluorescein isothiocyanate (FITC)-conjugated surface marker-specific mAbs for 1 hr 
at 4°: CD40 (clone 3/23), CD80 (clone RMMP-1), CD86 (clone RMMP-2), major 
histocompatibility complex (MHC) II-Ak (clone 14 V18), CD205 (clone NLDC-145) 
(all from Serotec, Oxford), CD11c (clone HL3) or CD54 (clone 3E2) (BD Biosciences, 
Oxford). Immunolabelling for PrP was carried out using the PrP-specific mAb 
8H420 followed by FITC-conjugated goat antimouse antibody (Caltag). Prior to their 
use in experiments all the above monoclonal antibodies were titrated to determine 
the concentration which would give 100% saturation. Appropriate FITC-conjugated 
antibodies were used as non-specific Ig-isotype controls (Serotec). All samples were 
fixed in 1% paraformaldehyde and flow cytometry conducted on a FACSCalibur ™ 
(Becton Dickinson, San Jose, CA) and data analysed using CELLQuest ™ software 
(Becton Dickinson). 
 
mRNA isolation and cDNA synthesis 
mRNA was isolated from XS106 cells using the µMACS mRNA Isolation Kit (Miltenyi 
Biotec Ltd, Bisley, Surrey) according to the manufacturer's instructions. To 
synthesize cDNA, 1 µl (25 µg) oligo (dT)12−18 primer (Invitrogen) and 12 µl diethyl 
pyrocarbonate (DEPC)-treated water was added to 100 ng of the isolated mRNA and 
incubated at 70° for 10 min; 4 µl 5× first strand buffer, 2 µl dithiothreitol (DTT) 
(0·1M) and 1 µl dNTP (10 mM; Invitrogen) were then added and incubated at 42° for 
2 min. Finally 1 µl of Superscript ™ II reverse transcriptase (Invitrogen) was added 
and incubated at 42° for 50 min. The reaction was stopped by incubation at 70° for 
15 min. 
 Analysis of PrP mRNA expression by reverse transcription-polymerase chain 
reaction (RT-PCR) 
The PCR mixture (total volume 60·2 µl) contained; 5 µl 10× PCR buffer, 1·5 µl 50 
mMMgCl, 1 µl 10 mM dNTP mix (Invitrogen), 1 µl cDNA, 0·5 µl (100 pmol/µl) of each 
specific primer, 0·2 µl Taq polymerase (Invitrogen) and 50 µl sterile DNase and 
RNase free water. The sequences of the specific primers used were as follows: 
Primer combination 1 
1. PrP Fwd-5′-AGG TTA ACT GAA CCA TTT CAA CCG AGC-3′ 
2. PrP Rev-5′-TCC CCC AGC CTA GAC CAC GAG A-3′ 
 
Primer combination 2 
1. PrP Fwd-5′-AGG TTA ACT GAA CCA TTT CAA CCG AGC-3′ 
2. PrP Rev-5′-GCT TGT TCC ACT GAT TAT GG-3′ 
 
Following a hot start at 94° for 3 min an amplification cycle was carried out for 30 
cycles at the following temperatures on a thermal cycler: 94° 30 seconds, 63° 30 
seconds, 72° 60 seconds. A final extension period at 72° for 10 min was included at 
the end of the 30 cycles. PCR products were resolved by electrophoresis at 125 V 
through a 1·5% agarose gel containing 1 µg/ml ethidium bromide. Primers 1 and 2 are 
designed to generate a 1000 base pairs (bp) fragment; primers 1 and 3 generate a 
400 bp fragment. 
 Analysis of Toll-like receptor (TLR)-2 and TLR-4 mRNA expression by RT-PCR 
The PCR mixture (total volume 60·2 µl) contained: 5 µl 10× PCR buffer, 1·5 µl 50 
mMMgCl, 1 µl 10 mM dNTP mix, 1 µl cDNA, 0·5 µl (100 pmol/µl) of each specific 
primer, 0·2 µl Taq polymerase and 50 µl sterile DNase and RNase free water. The 
sequences of the specific primers used were as follows: 
 TLR-2 Fwd-5′-GTCTCTGCGACCTAGAAGTGGA-3′ 
 TLR-2 Rev-5′-CGGAGGGAATAGAGGTGAAAGA-3′ 
 TLR-4 Fwd-5′-GCAATGTCTCTGGCAGGTGTA-3′ 
 TLR-4 Rev-5′-CAAGGGATAAGAACGCTGAGA-3′ 
Following a hot start at 94° for 2·5 min an amplification cycle was carried out for 32 
cycles at the following temperatures on a thermal cycler: TLR-2, 94° 30 seconds, 56° 
30 seconds, 72° 45; TLR-4, 95° 45 seconds, 61° 45 seconds, 72° for 45 seconds, for 36 
cycles. A final extension period at 72° for 10 min was included at the end of the 
cycles. PCR products were resolved by electrophoresis at 125 V through a 1·5% 
agarose gel containing 1 µg/ml ethidium bromide. Primers for TLR-2 are designed to 
generate a 336 bp fragment; primers for TLR-4 are designed to generate a 406 bp 
fragment. 
 
Exposure of cells to scrapie 
For scrapie inoculation studies, sterile glass coverslips were placed in the wells of a 
flat-bottomed 24-well plate (Corning, Buckinghamshire). Cells (5 × 105 in 1 ml of 
cRPMI) were seeded into each well. When confluent (approx. 2 × 106 cells/coverslip), 
each well was inoculated with 10 µl of 10% (wt/vol) brain homogenate from a 
terminally ME7 scrapie-affected C57BL/Dk mouse (equivalent to 1·0 mg tissue). 
Duplicate sets of culture cells were inoculated with 10 µl of 10% (wt/vol) uninfected 
mouse brain homogenate in cRPMI as a control. The medium was removed after 16 
hr incubation at 37° in a 5% CO2/air atmosphere and cells in each well washed 
extensively with fresh medium by pipetting. Cells were then maintained for the times 
indicated before further analysis. Where indicated some cells were stimulated with 
10 ng/ml of lipopolysaccharide (LPS, serotype 055:B5; Sigma) 1 hr before exposure 
to the scrapie agent. 
 
Immunofluorescent confocal microscopy 
Following exposure to the scrapie agent, cells were washed and cytospin preparations 
prepared (approximately 1 × 105 per slide). Cytospins were fixed in methanol at −20° 
for 20 min and non-specific binding sites blocked with 3% BSA for 1 hr. Non-specific 
binding to Fc-receptors was blocked by addition 0·1 µg of mouse mAb CT-17·2 
(Caltag). Avidin/biotin binding sites were blocked subsequently using the 
avidin/biotin blocking kit (Vector Laboratories, Peterborough) according to the 
manufacturer's instructions. PrP was detected using the PrP-specific mouse mAb 
8H420 followed by biotin-conjugated goat antimouse antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA). Immunolabelling was carried out 
using Alexa 488-conjugated streptavidin (Biosciences, Cambridge). Cell nuclei were 
distinguished using DAPI nucleic acid stain (Biosciences). 
 
Cell immunoblot detection of PrP Sc 
PrPSc accumulations were determined by the cell immunoblot procedure.21 Briefly, 
coverslips were removed and the cell-bearing side blotted onto polyvinylidine 
difluoride membranes (Bio-Rad, Hemel Hempstead), treated with proteinase K, 
denatured with guanidine isothiocyanate and PrP detected using the PrP-specific 
mAb 8H4.20 Immunolabelling was carried out using horseradish peroxidase-
conjugated goat antimouse IgG antiserum (Jackson ImmunoResearch Laboratories 
Inc.), and bound horseradish peroxidase activity detected with Supersignal ® West 
Dura Extended Duration Substrate (Pierce, Chester). After exposure, membranes 
were stained with 0·5 µg/ml ethidium bromide and observed in UV light to confirm 
transfer of the cell layer.22 
 
Determination of scrapie agent infectivity 
Following exposure to the scrapie agent for the times indicated cells were dislodged 
using a rubber policeman and washed twice in Hanks's balanced salt solution 
(HBSS). Viable cell numbers were determined by trypan blue dye exclusion. Cell 
pellets were resuspended in an appropriate volume of sterile PBS to give 2 × 105 cells 
per 20 µl dose. Cells were lysed by 10 successive rapid freeze–thaw cycles at the 
temperature of liquid nitrogen. Non-infected cells or cells exposed to normal brain 
homogenate were used as reference controls. Cell lysates (20 µl) were injected 
intracranially (i.c.) into groups of nine C57BL/Dk indicator mice. The scrapie titre in 
each lysate was estimated from the mean incubation period from a dose/incubation 
period response curve for scrapie-infected spleen tissue.23 Infectivity titres are 
expressed as 50% infectious dose units per 106 cells (ID50/106 cells). 
Statistical tests 
Data from individual experiments are presented and are representative of data from 
two to five experiments. Where applicable, the statistical significance of differences 
between the means for each experimental group were calculated using ANOVA one-
way analysis with Minitab software. A P-value = 0·05 was considered to be 
significantly different. 
 
Results 
Characterization of the XS106 cell line 
Prior to use in experiments the surface phenotype of the XS106 cells was determined. 
FACS analysis confirmed that the XS106 cells expressed the following surface 
markers: CD11c, CD40, CD54, CD80, CD86, CD205 and Iak (MHC-II) (Fig. 1b–h, 
respectively). Daily analysis of XS106 cells for 4 further days in culture demonstrated 
that this surface phenotype remained unchanged during the observation period (data 
not shown). 
XS106 cells express PrPC 
Next, the expression of PrPC protein and mRNA by XS106 cells was determined. 
FACs analysis demonstrated that the majority of the XS106 cells expressed 
PrPC protein on their surfaces (Fig. 1i). The expression of PrP-specific mRNA was 
confirmed using two different sets of primers by the visualization of a single band at 
1000 bp using primer combination 1 (Fig. 1j, lanes 1 and 2) and also a single band at 
400 bp using primer combination 2 (Fig. 1j, lanes 3 and 4). 
XS106 cells rapidly acquire scrapie-affected brain homogenate 
We next determined whether XS106 cells could acquire the scrapie agent after in 
vitroexposure. Cells were exposed to terminally scrapie-affected brain homogenate 
for 10 min, 30 min, 16 hr or 24 hr. Uninfected cells and cells exposed to an equivalent 
amount of uninfected (normal) brain homogenate were included as controls. 
Immunofluorescent confocal analysis of cytospin preparations revealed abundant 
accumulations of PrP in association with the XS106 cells within 10 min of exposure 
to scrapie-affected brain homogenate (Fig. 2, panel c). Visually, the strongest 
labelling for PrP was detected after 30 min of exposure to the scrapie brain 
homogenate (Fig. 2, panel f). Thereafter, the intensity of PrP staining appeared to 
decrease during the 24-hr observation period (Fig. 2, panels i and l). Accumulations 
of PrP were also detected in association with XS106 cells exposed to normal brain 
homogenate over the same time period (Fig. 2, panels, b, e, h and k). In contrast, the 
level of PrP immunolabelling detected in association with unexposed cells (Fig. 2, 
panels a, d, g and j) was visibly less when compared to cells exposed to either scrapie 
brain homogenate or normal brain homogenates. Thus, these data appear to show 
that XS106 cells rapidly acquire scrapie-affected and normal brain homogenate 
after in vitro exposure. However, as the PrP-specific mAb 8H4 does not distinguish 
between the cellular PrPC or scrapie agent-specific PrPSc isoforms, it was not possible 
to determine immunocytochemically whether the PrP detected was PrPSc, PrPC from 
the brain homogenate or enhanced expression of PrPC by XS106 cells in response to 
the brain homogenate. 
XS106 cells acquire and degrade PrPSc and infectivity 
To investigate further whether XS106 cells acquire PrPSc following exposure to 
scrapie brain homogenate, cellular accumulations of agent-specific proteinase K 
(PK)-resistant PrPSc were analysed by cell immunoblotting. Monolayers of XS106 
cells were cultured on sterile glass coverslips and then exposed to terminally scrapie-
affected brain homogenate for 16 hr. Cells were then washed to remove excess brain 
homogenate and maintained in culture for up to 96 hr. Uninfected cells and cells 
exposed to normal brain homogenate were included as controls. Following 
inoculation, coverslips were removed and PrPSc levels determined by cell 
immunoblotting. 
XS106 cells exposed to scrapie brain homogenate and assayed immediately after 
washing (16 hr) or 24 hr after exposure contained abundant levels of PK-resistant 
PrPSc(Fig. 3a). However, analysis of cells from 48 hr onwards suggested that the 
levels of PrPSc detected progressively decreased over the 96-hr observation period 
(Fig. 3a18). In contrast, no PrPSc was detected in association with cells exposed to 
normal brain homogenate (Fig. 3a) or unexposed cells (Fig. 3c) as controls. The 
successful transfer of cells to the membranes was confirmed by the detection of 
cellular DNA on membranes for each cell transfer (Fig. 3b). No PrPSc or DNA was 
detected in association with cell-free cover-slips exposed to scrapie brain 
homogenate as a control (Fig. 3d), confirming that the PrPSc detected in the above 
instances (Fig. 3a) was cell-associated and not simply adhered to the coverslip. No 
significant effect on cell viability or metabolic activity was observed following 
exposure of the cells to scrapie brain homogenate when compared to those exposed 
to normal brain homogenate or medium alone, as controls (data not shown). Thus 
the reduction in the PrPSc associated with the XS106 LC-like cells was unlikely to be 
due to reduced cell viability. A further experiment was included to determine 
whether the reduced detection of PrPSc in association with XS106 cells was due to 
masking the epitope recognized by mAb 8H4. The PrP-specific mAb 7A12 recognizes 
an epitope contained within amino acid residues 122–143 of the PrP protein which is 
distinct from the epitope recognized by mAb 8H4 (amino acids 147–16420). The level 
of PrPSc detected following exposure of XS106 cells to scrapie brain homogenate was 
similarly visibly reduced over the 96-hr observation period when mAb 7A12 was used 
to detect PrPSc (Fig. 3e). 
To determine whether the degradation of PrPSc by XS106 cells correlated with a 
reduction in scrapie infectivity, lysates were prepared from XS106 cells exposed to 
scrapie-affected brain homogenate and infectivity titres determined by incubation 
period assay by i.c. injection into nine C57BL/Dk indicator mice. Lysates prepared 
from uninfected XS106 cells and cells exposed to normal brain homogenate were 
included as negative controls. After 16 hr exposure to scrapie brain homogenate the 
cells had acquired approximately 5·9 log i.c. ID50/106 cells (Fig. 4a). Statistical 
analysis of the means of the disease incubation periods for each group of indicator 
mice injected with homogenate prepared 16 hr (190 ± 2 days, n = 9) or 24 hr (188 ± 3 
days, n = 9) after exposure suggested there was no significant difference between the 
infectivity titres associated with these cells at 16 hr and 24 hr postexposure (P 
= 0·659,ANOVA, n = 9). However, by 96 hr after exposure the infectivity titre had 
declined to approximately 4·4 log i.c. ID50/106 cells (Fig. 4a). Comparison of the 
mean disease incubation period obtained from mice injected with 96-hr 
homogenates (220 ± 9 days,n = 9) with those measured at both 16 hr and 24 hr 
postexposure suggested the infectivity titre measured after 96 hr exposure was 
significantly lower (P = 0·007 andP = 0·008, respectively, ANOVA, n = 9). Scrapie 
infectivity was undetectable in preparations of normal brain homogenate alone or 
lysates of uninfected cells or cells exposed to normal brain homogenate (Fig. 4a). 
These data confirm that the degradation of PrPSc by XS106 cells correlated with a 
significant reduction in the level of scrapie agent infectivity associated with these 
cells. 
Effect of scrapie exposure on the surface expression of costimulatory and activation 
markers by XS106 cells 
FACS analysis was used to determine whether the expression of specific surface 
antigens by XS106 cells was altered following exposure to the scrapie agent. The 
experiment demonstrated that exposure to the scrapie agent did not significantly 
change the expression of CD11c, CD40, CD54, CD80, CD86, CD205, Iak or PrP when 
compared to cells exposed to normal brain homogenate (Fig. 5). These data suggest 
that XS106 cells do not undergo further maturation or activation after in 
vitroexposure to the scrapie agent. 
Immature LC-like cells do not degrade the scrapie agent in vitro 
Unlike the XS106 cell line used above, the XS52 cell line is an immature LC-like cell 
line isolated from mouse epidermis.19 FACS analysis confirmed that these cells do 
not express the surface antigens typically associated with LC maturation (CD40, 
CD80, CD86 and Iad; Fig. 6a–d, respectively), indicating that these cells displayed an 
immature phenotype when compared to XS106 cells (Fig. 1). However, XS52 cells 
expressed PrPC protein (Fig. 6e). The XS52 cell line was used in parallel studies to 
determine whether the degradation of PrPSc by XS106 cells is typical of any in 
vitrocultivated cell line exposed to the scrapie agent. Under the same experimental 
conditions, XS52 cells accumulated abundant PrPSc after 16 hr exposure to scrapie 
brain homogenate (Fig. 6f). However, in contrast to XS106 cells exposed to the 
scrapie agent (Figs 3a and and4a),4a), there was no progressive decrease in 
PrPSc (Fig. 6f) or infectivity (Fig. 4b) over the 96-hr observation period. 
LPS inhibits the degradation of PrPSc by XS106 cells 
As non-specific immune stimulation around the time of peripheral inoculation with 
TSE agents can enhance disease pathogenesis24 we next investigated the effect of LPS 
stimulation on PrPSc degradation by XS106 cells. LCs can bind LPS via Toll-like 
receptor (TLR)-2 and TLR-425,26 in association with CD14.27 RT-PCR analysis 
confirmed that XS106 cells expressed mRNA specific for both TLR-2 (Fig. 7a) and 
TLR-4 (Fig. 7b). The demonstration that XS cells also express CD1428 indicates that 
these cells would have the potential to respond to LPS stimulation. LPS pretreatment 
appeared to block the degradation of PrPSc by XS106 cells, as cells stimulated with 
LPS prior to exposure to the scrapie agent showed no decrease in PrPSc over the 96-
hr observation period (Fig. 7c). 
 
Discussion 
Here we show that LC-like XS106 cells rapidly acquire the scrapie agent following in 
vitro exposure. After uptake, the PrPSc and infectivity levels associated with the 
scrapie agent-exposed XS106 cells were significantly degraded with extended 
cultivation. These data suggest that LCs might acquire and degrade the scrapie agent 
after inoculation via the skin. Highly immature XS52 LC-like cells acquired but did 
not significantly degrade the scrapie agent following in vitro exposure. The ability of 
XS106 cells to degrade PrPSc was lost following stimulation with LPS implying that 
the ability of LCs to degrade PrPSc might be blocked in the presence of 
immunostimulatory molecules within the epidermis. Exposure to the scrapie agent 
did not alter the surface expression of PrPC or a variety of costimulatory or activation 
markers on the XS106 cells. These data suggest that LCs or skin DCs have the 
potential to acquire and degrade the scrapie agent within the epidermis but would 
not undergo further maturation. 
Following uptake by DCs, antigens are usually processed into short peptides for 
presentation to T lymphocytes in association with MHC. However, in some 
circumstances DCs can retain protein antigens in a native, non-degraded form.29 The 
precise fate of the scrapie agent following uptake by DCs is unclear, as studies have 
shown these cells can retain16 or degrade PrPSc.30 Thus we investigated the actions of 
LC-like cells on the scrapie agent following in vitro exposure. Immunofluorescent 
confocal analysis demonstrated that, following exposure to scrapie brain 
homogenate, XS106 cells contained heavy intracellular deposits of PrP. Further 
experiments demonstrated that these PrP deposits contained PrPSc and infectivity 
which was subsequently degraded following extended cultivation. The mechanism 
through which XS106 cells degrade the scrapie agent is not known, but may be 
mediated by cysteine proteases as shown for the degradation of PrPSc by bone 
marrow-derived CD11c+myeloid DCs.31 Accumulations of PrPSc and infectivity were 
also detected in association with the highly immature XS52 LC-like cell line following 
exposure to the scrapie agent. However, the levels of PrPSc and infectivity associated 
with this cell line were not subsequently degraded. These data imply that the ability 
of LCs or DCs to acquire and partially degrade the scrapie agent may be related to the 
maturation status of the cells. 
Exogenous stimuli such as inflammatory cytokines,32 CpG oligonucleotides33 and 
LPS34 induce the activation and maturation of LCs. Studies by Sethi et al.35 have 
shown that treatment of mice with CpG oligonucleotides extended the survival time 
of scrapie agent-inoculated mice. The effect of CpG treatment on disease 
pathogenesis was considered to be due to the enhanced clearance of the scrapie agent 
by TLR-stimulated DCs or macrophages.35 As LCs26 and XS106 cells (Fig. 7) express 
TLR-2 and TLR-4 which bind LPS, we investigated whether LPS-stimulation would 
enhance the degradation of PrPSc by XS106 cells. However, we found that LPS-
stimulation blocked the degradation of PrPSc by XS106 cells. These data appeared to 
be in opposition to the hypothesis that TLR-mediated stimulation of the innate 
immune system enhances the degradation of the scrapie agent.35 However, 
subsequent data show that the CpG oligonucleotide treatment protocol used by 
Sethi et al.35 destroys lymphoid follicles,36 the main peripheral site of replication for 
the scrapie agent.7,8Furthermore, it is unlikely that TLR-mediated stimulation plays 
an important role in the degradation of the scrapie agent as disease pathogenesis is 
unaffected in Myd88–/–mice with defective TLR signalling.37 The mechanism 
through which LPS blocks the degradation of PrPSc by XS106 cells is unknown. 
Because LPS-induced proteolytic activity may be accompanied by a down-regulation 
in antigen uptake via macropinocytosis or Fc-receptors,38 the loss of 
PrPSc degradation by LPS-stimulated XS106 cells may reflect a diminished uptake of 
the scrapie agent by the cells. Treatment with LPS prior to inoculation with the 
scrapie agent increases the efficiency of infection.24 Together these data suggest the 
effects of LPS treatment on disease pathogenesis might be due to the impaired 
clearance of the scrapie agent by macrophages or DCs at the site of inoculation. 
Indeed, depletion of macrophages before peripheral inoculation with the scrapie 
agent increases the accumulation of infectivity and PrPSc in the spleen and shortens 
the incubation period.39 
DCs in peripheral tissues, including epidermal LCs, are resting cells that 
continuously endocytose antigens from their local environment. These cells express 
very low levels of MHC class II and no costimulatory molecules.13 Following antigen 
encounter and appropriate stimulation, LCs become activated and up-regulate the 
expression of MHC class II, and a variety of costimulatory molecules including 
CD11c, CD40, CD54 (ICAM-1), CD80 and CD86 on their surfaces transforming the 
cells from immature to mature LCs.40–42 This transformation enables the LCs to 
present endocytosed antigens on their surfaces in association with MHC class II, 
express costimulatory molecules to interact with T cells and stimulates their 
migration to draining lymph nodes. In the current study, surface marker expression 
on XS106 cells did not significantly change following exposure to the scrapie agent, 
implying that the cells were not specifically activated. These observations are 
congruent with the demonstration that antigen endocytosis alone does not induce DC 
activation.43 These data do not reflect those reported by Bacot et al. who have shown 
that the prion protein peptide PrP106−126 induces the up-regulation of HLA-DR, 
CD40, CD80 and CD83 on the surface of human monocyte-derived DCs.44 Whether 
DCs respond differently to recombinant PrP106−126 and the scrapie agent is not 
known. The magnitude of surface marker expression on the XS106 cells used in the 
current study suggests it is unlikely these cells were terminally mature and could not 
undergo further maturation following scrapie agent exposure. The effect of scrapie 
exposure on the surface expression of the C-type lectin CD205 was also analysed as 
this receptor binds carbohydrate residues and delivers them to lysosomes or late 
endosomes for degradation.45 Although these cellular compartments have been 
proposed as sites for PrPSc degradation,46–48 expression of CD205 was similarly 
unaffected following exposure to the scrapie agent. 
Following inoculation of mice with the scrapie agent via the skin, neuroinvasion 
occurs after the agent accumulates in association with FDCs in the draining lymph 
node.5,6 The mechanism through which the scrapie agent is transported to the FDCs 
within draining lymph node following inoculation via the skin is not known. Upon 
antigen encounter LCs receive a complex network of signals which stimulate their 
maturation and migration to draining lymphoid tissue.13 In mice, inoculation with 
the scrapie agent does not elicit a specific humoral or cell-mediated immune 
response.49,50 Our data above similarly predict that LCs would not become 
specifically activated following exposure to the scrapie agent in the epidermis. Thus, 
although LCs have the potential to acquire and degrade the scrapie agent within the 
epidermis, our data suggest it is unlikely that these cells become activated and are 
stimulated to transport the agent to the draining lymph node. Indeed, we have 
recently demonstrated that when LC migration from the epidermis is blocked, 
scrapie infectivity is still able to reach the draining lymph node following inoculation 
via the skin suggesting, that LCs are not major TSE agent transporters.18 
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Fig 1. 
 
 
(a–i) FACS analysis of the surface antigen phenotype of XS106 cells. XS106 cells were gated as shown 
(a). Cells were stained with a panel of FITC-conjugated mAbs specific for the following antigens: 
CD11c (b), CD40 (c), CD54 (d), CD80 (e), CD86 (f), CD205 (g), Iak(h) and PrP (i) Bold histograms 
represent cells stained with surface antigen-specific mAbs, fine histograms represent cells stained 
with isotype-matched, non-specific FITC-conjugated control mAbs. (j) XS106 cells express mRNA for 
PrPC. RT-PCR analysis confirmed the presence of PrPC-specific mRNA by the visualisation of a single 
band at 1000 bp (lanes 1 and 2; using primer combination (1) and also a single band at 400 bp (lanes 
3 and 4; using primer combination (2). Lane M, 100 bp molecular size markers. Lane C, non-reverse 
transcriptase treated mRNA preparation from XS106 cells as a control. 
Fig.2 
 
 
XS106 cells rapidly acquire scrapie brain homogenate. Immunofluorescent confocal analysis 
of cytospin preparations detected the presence of abundant intracellular accumulations of PrP 
(green) within XS106 cells exposed to scrapie brain homogenate (scrapie; panels c, f, i and l) 
when compared to unexposed cells (control; panels a, d, g and j). Intracellular PrP 
accumulations were also detected within XS106 cells exposed to normal brain homogenate 
(NBr; panels b, e, h and k). Cells were exposed to scrapie or NBr for 10 min (top row), 30 min 
(second row), 16 hr (third row) or 24 hr (bottom row) before analysis. (m) unexposed cells 
stained with an isotype-matched, non-specific FITC-conjugated mAb as a control. Original 
magnification ×40. All sections were counterstained with DAPI to detect cell nuclei (blue). 
Fig.3 
 
 
XS106 cells acquire and degrade PrPSc. Duplicate cultures of XS106 cells were exposed to 
either normal brain homogenate (NBr) or scrapie brain homogenate (ME7) for 16 hr, washed 
and then maintained in culture for the times indicated. Cells were then transferred to PVDF 
membranes and treated in the absence (–) or presence (+) of PK before immunostaining with 
PrP-specific mAb 8H4 (a) or 7A12 (e) Cell immunoblot analysis showed a progressive 
decrease in the levels of PK resistant PrPSc associated with the scrapie-exposed XS106 cells 
over the 96-hr observation period (a and e). No PrPSc was detected in association with XS106 
cells exposed to NBr (a and e), unexposed XS106 cells (c) or cell-free coverslips exposed to 
scrapie brain homogenate (d) Ethidium bromide (EthBr) staining of the PVDF membranes 
confirmed the transfer of cellular DNA (b, c and f). Panel (a) is adapted from Mohan et al.18 
 
 
 
 
 
 
Fig.4 
 
 
XS106 cells acquire and degrade scrapie agent infectivity. Duplicate cultures of XS106 cells (a) 
or XS52 cells (b) were exposed to either normal brain homogenate (NBr) or scrapie brain 
homogenate (ME7) for 16 hr, washed and then maintained in culture for the times indicated. 
Cell lysates were then prepared and scrapie agent infectivity titres determined by incubation 
period assay by i.c. injection of the lysates into groups of nine indicator mice. Infectivity titres 
are expressed as ID50/106 cells. *All indicator mice remained free of the signs of scrapie up to 
at least 400 days after inoculation suggesting an infectivity titre, if present, below 100 
ID50/106 cells. 
 
Fig.5 
 
 
 
Effect of exposure to the scrapie agent on surface antigen expression by XS106 cells. Before FACS 
analysis cells were stained with a panel of FITC-conjugated mAbs specific for the following antigens: 
CD11c, CD40, CD54, CD80, CD86, CD205, Iak and PrP. Bold histograms represent cells exposed to 
scrapie brain homogenate, fine histograms represent cells exposed to normal brain homogenate. 
Fig.6 
 
 
XS52 cells acquire but do not degrade the scrapie agent. (a–e) FACS analysis of the surface antigen 
phenotype of XS52 cells. Cells were stained with a panel of FITC-conjugated mAbs specific for the 
following antigens: CD40 (a), CD80 (b), CD86 (c), Iak (d) and PrP (e). Bold histograms represent 
cells stained with surface antigen-specific mAbs, fine histograms represent cells stained with isotype-
matched, non-specific FITC-conjugated control mAbs. (f and g) Duplicate cultures of XS52 cells were 
exposed to either normal brain homogenate (NBr) or scrapie brain homogenate (ME7) for 16 hr, 
washed and then maintained in culture for the times indicated. Cells were then transferred to PVDF 
membranes and treated in the absence (–) or presence (+) of PK before immunostaining with the PrP-
specific mAb 8H4. Cell immunoblot analysis showed scrapie agent exposed XS52 cells acquired 
PrPSc but did not degrade it over the 96-hr observation period (f). Ethidium bromide staining of the 
PVDF membranes confirmed the transfer of cellular DNA (g). Panel (f) is adapted from Mohan et al.18 
 
Fig.7 
 
 
LPS stimulation blocks the degradation of PrPSc by XS106 cells. (a and b) RT-PCR analysis confirmed 
that XS106 cells express mRNA specific for TLR-2 (a, lanes 1 and 2, single band at 336 bp) and TLR-4 
(b, lanes 1 and 2, single band at 406 bp). Lane M, 100 bp molecular size markers. Lane C, non-reverse 
transcriptase treated mRNA preparation from XS106 cells as a control. (c) Duplicate cultures of 
XS106 cells treated with LPS and 1 hr later exposed to either normal brain homogenate (NBr) or 
scrapie brain homogenate (scrapie) and LPS for 16 hr, washed and then maintained in culture for the 
times indicated. Cells were then transferred to PVDF membranes and treated in the absence (–) or 
presence (+) of PK before immunostaining with the PrP-specific mAb 8H4. The PrPSc associated with 
LPS-treated scrapie agent exposed XS106 cells was not degraded over the 96-hr observation period (c) 
when compared to non-LPS treated scrapie agent-exposed XS106 cells (d). 
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